Clinical Study Report - Calidad de Información CFR
Clinical Study Report - Calidad de Información CFR
Clinical Study Report - Calidad de Información CFR
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
source data document, If there were any discrepancies, they were noted on the CRF, and<br />
investigators took corrective actions. All the medical records were ma<strong>de</strong> avaible for review and<br />
clarification..<br />
The pharmacist was <strong>de</strong>legated IP management by the principal investigator. The pharemacit<br />
received IP, checked the quantity, and managed IP in general. IP adminstration followed the<br />
protocol and instruction. Unused IP was retrieved by Sponsor; every unused drug, used/unused<br />
vials, labels, and copies of IP management document were sent to the monitor at the end of<br />
the trial.<br />
During the trial, monitors visited study centers regularly to mointor whether the trial was<br />
following the protocol, standard operation procedures, KGCP, and related regulations and<br />
guidliens. The source document was ma<strong>de</strong> to monitors, auditors, and IRB. Monitors could<br />
always access the entire source documents including CRFs, copies of laboratory result, and<br />
medical test results, and verified CRF entries and signed consents against the source document.<br />
The investigator collected and recor<strong>de</strong>d all the AEs. The investigator reported SAEs to IRBs and<br />
the sponsor according to the “Chapter 17. Gui<strong>de</strong>lines for adverse events” of the protocol. The<br />
SAE recporting procedure is consistent with the LSK SOP and related regulations.<br />
Data were transferred into database using DMSys 4.0, SigmaSoft International, Florida USA, by<br />
two entry persons. File comparison was performed. Medical Dictionary for Drug Regulatory<br />
Affairs(MedDRA) and Drug Reference list (Anatomic Therapeutic Chemical co<strong>de</strong>:ATC co<strong>de</strong>) were<br />
used to perform the medical coding of adverse events and medications.<br />
Data clarification forms (DCFs) were issued to query CRF entries. Consistency between essential<br />
documents for trial master files and essential documents for investigator site files was<br />
maintained. Corrections of CRF entries were reviewed and approved by the investigators.<br />
The datebase was locked on Februaty 08 th , 2006.<br />
9.7. Statistical methods planned in the protocol and <strong>de</strong>termination of<br />
sample size<br />
CSR_Clotinab_II 36<br />
Ver. 1.0_Eng